Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.53), $0.06 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $40 thousand versus the consensus estimate of $13.47 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.